Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*Ángel Crespo López, Robert F. Grover, Jan Bakker et al.|Critical Care Medicine|2004Cited by 921